Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Markets

RELX and ConvaTec among the names in Thursday’s diary

RELX is expected to see revenue and profit growth, whereas ConvaTec will report on what's seen as a disappointing year.
London Stock Exchange
The diary is a little light at the stock exchange

Electronic databases specialist RELX Group PLC (LON:REL) is expected to report another year of underlying revenue, profit and earnings growth on Thursday.

Revenue growth on the Scientific, Technical & Medical side and in the Legal business is expected to be modest, having been up 2% year-on-year in the first nine months of the financial year.

The sexy numbers should be provided by the Risk & Business Analytics (R&BA) division, which has seen strong revenue growth across all segments of the division.

The R&BA division saw underlying revenue growth of 8%, which topped the 5% growth seen in the Exhibitions business.

Margins under pressure ConvaTec

Colostomy bag maker ConvaTec Group PLC’s (LON:CTEC) first full year after its IPO has proven to be something of a disappointment.

Product supply in wound care and ostomy has been hampered by the implementation of the gross margin improvement plan, although margins are still likely to have slipped last year.

Results for the 12 months to December 31 are due on Thursday, and the FTSE 250 group is expected to deliver sales growth of 1.5% to US$1.75bn, according to City broker Numis.

But the gross margin is tipped to fall to 61% which means underlying earnings are forecast to dip to US$451mln (2016: US$472.2mln), while adjusted earnings per share is seen as slipping to US$0.165 (2016: US$0.183).

“Assuming no further fall in cash conversion (75% in H1, 80% in FY16), the focus should be on the outlook for FY18, where we forecast 2.4% organic growth on constant currency (consensus c.2-3%), flat gross margins (FX headwinds) and increased opex (NSe 37% of sales),” said Numis analyst Paul Cuddon.

Cuddon reckons sales and marketing and R&D investment will rise this year as ConvaTec battles its way through a “harsher competitive environment”, while the analyst is also looking for guidance on the implications from the recently-introduced US tax cuts.

Thursday February 15:

Finals: RELX PLC (LON:REL), ConvaTec PLC (LON:CTEC), Indivior PLC (LON:INDV), Lancashire Holdings PLC (LON:LRE), Primary Health Properties PLC (LON:PHP)

Interims: InnovaDerma PLC (LON:IDP)

Trading update: Aveva Group PLC (LON:AVV)

Ex-dividends: To knock 24.4 points off FTSE 100: AstraZeneca PLC (LON:AZN), BP PLC (LON:BP.), Hargreaves Lansdown PLC (LON:HL.), Royal Dutch Shell PLC (LON:RDSA) (LON:RDSB), Unilever plc (LON:ULVR)

Economic data: EU preliminary GDP; US weekly jobless; US industrial production; US forward PPI; Philly Fed business outlook; Empire State manufacturing survey


No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use